Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab


Besbas N., Gulhan B., Karpman D., Topaloglu R., Duzova A. , Korkmaz E., ...More

PEDIATRIC NEPHROLOGY, vol.28, no.1, pp.155-158, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.1007/s00467-012-2296-4
  • Title of Journal : PEDIATRIC NEPHROLOGY
  • Page Numbers: pp.155-158

Abstract

Atypical hemolytic uremic syndrome (aHUS) is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment. Neonatal cases are extremely uncommon. Plasma therapy is the first choice therapy in patients with aHUS based on the belief of an underlying complement dysregulation. Alternatively, eculizumab, which targets complement 5, is used to block complement activation.